Improved antileishmanial activity of dppz through complexation with antimony(III) and bismuth(III): Investigation of the role of the metal

Molecules

Volumn 17, Issue 11, 2012, Pages 12622-12635

  Lizarazo Jaimes, Edgar H ^a   Monte Neto, Rubens L ^a   Reis, Priscila G ^a   Fernandes, Nelson G ^a   Speziali, Nivaldo L ^a   Melo, Maria N ^a   Frézard, Frédéric ^a   Demicheli, Cynthia ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antimony; Bismuth; Crystal structure; Dipyrido 3,2 a:2 ,3 c phenazine; Drug resistance; Leishmania

Indexed keywords

ANTIMONY; ANTITRYPANOSOMAL AGENT; BISMUTH; COORDINATION COMPOUND; DIPYRIDO(3,2 A 2',3' C)PHENAZINE; DIPYRIDO(3,2-A-2',3'-C)PHENAZINE; PHENAZINE DERIVATIVE;

ANIMAL; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; IC 50; INFRARED SPECTROSCOPY; LEISHMANIA; MOUSE; PERITONEUM MACROPHAGE;

ANIMALS; ANTIMONY; BISMUTH; CELLS, CULTURED; COORDINATION COMPLEXES; DRUG RESISTANCE; INHIBITORY CONCENTRATION 50; LEISHMANIA; MACROPHAGES, PERITONEAL; MICE; MOLECULAR STRUCTURE; PHENAZINES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRYPANOCIDAL AGENTS;

EID: 84870216837     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules171112622     Document Type: Article

References (45)

1. Marsden, P.D. Pentavalent antimonials: Old drugs for new diseases. Rev. Soc. Bras. Med. Trop. 1985, 18, 187-198.
2. Frézard, F.; Demicheli, C.; Ribeiro, R.R. Pentavalent antimonials: New perspectives for old drugs. Molecules 2009, 14, 2317-2336.
3. Frézard, F.; Demicheli, C.; Ferreira, C.S.; Costa, M.A.P. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob. Agents Chemother. 2001, 45, 913-916.
4. Ferreira, C.D.; Martins, P.S.; Demicheli, C.; Brochu, C.; Ouellette, M.; Frézard, F. Thiol-induced reduction of antimony(V) into antimony(III): A comparative study with trypanothione, cysteinylglycine, cysteine and glutathione. Biometals 2003, 16, 441-446.
5. Sundar, S.; More, D.K.; Singh, M.K.; Singh, V.P.; Sharma, S.; Makharia, A.; Kumar, P.C.K.; Murray, H.W. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin. Infect. Dis. 2000, 31, 1104-1107.
6. Ouellette, M.; Légaré, D.; Haimeur, A.; Grondin, K.; Roy, G.; Brochu, C.; Papadopoulou, B. ABC transporters in Leishmania and their role in drug resistance. Drug Resist. Updat. 1998, 1, 43-48.
7. Légaré, D.; Richard, D.; Mukhopadhyay, R.; Stierhof, Y.D.; Rosen, B.P.; Haimeur, A.; Papadopoulou, B.; Ouellette, M. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 2001, 276, 26301-26307.
8. V reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 2001, 276, 3971-3976.
9. Gourbal, B.; Sonuc, N.; Bhattacharjee, H.; Légaré, D.; Sundar, S.; Ouellette, M.; Rosen, B.P.; Mukhopadhyay, R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 2004, 279, 31010-31017.
10. Ayres, D.C.; Pinto, L.A.; Giorgio, S. Efficacy of pentavalent antimony, amphotericin B, and miltefosine in Leishmania amazonensis-infected macrophages under normoxic and hypoxic conditions. J. Parasitol. 2008, 94, 1415-1417.
11. Silvestru, C.; Socaciu, C.; Bara, A.; Haiduc, I. The first organoantimony(III) compounds possessing antitumor properties: Diphenylantimony(III) derivatives of dithiophosphorus ligand. Anticancer Res. 1990, 10, 803-804.
12. Sereno, D.; Holzmuller, P.; Mangot, I.; Cuny, G.; Ouaissi, A.; Lemesre, J.L. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob. Agents Chemother. 2001, 45, 2064-2069.
13. Moreira, W.; Leprohon, P.; Ouellette, M. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis. 2011, 2, 1-8.
14. Wyllie, S.; Fairlamb, A.H. Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line. Biochem. Pharmacol. 2006, 71, 257-267.
15. Cunningham, M.L.; Fairlamb, A.H. Trypanothione reductase from Leishmania donovani Purification, characterization and inhibition by trivalent antimonials. Eur. J. Biochem. 1995, 230, 460-468.
16. Baiocco, P.; Colotti, G.; Franceschini, S.; Ilari, A. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem. 2009, 52, 2603-2612.
17. Klapotke, T. Biological activity of organometallic bismuth compounds. Biol. Met. 1988, 1, 69-76.
18. Yang, N.; Sun, H. Biocoordination chemistry of bismuth: Recent advances Coord. Chem. Rev. 2007, 251, 2354-2366.
19. Andrews, P.C.; Frank, R.; Junk, P.C.; Kedzierski, L.; Kumar, I.; MacLellan, J.G. Anti-Leishmanial activity of homo- and heteroleptic bismuth(III) carboxylates. J. Inorg. Biochem. 2011, 105, 454-461.
20. Ensafi, A.A.; Hajian, R.; Ebrahimi, S. Study on the interaction between Morin-Bi(III) complex and DNA with the use of methylene blue dye as a fluorophor probe. J. Braz. Chem. Soc. 2009, 20, 266-276.
21. Oliveira, L.G.; Silva, M.M.; de Paula, F.C.S.; Pereira-Maia, E.C.; Donnici, C.L.; de Simone, C.A.; Frézard, F.; da Silva Junior, E.N.; Demicheli, C. Antimony(V) and bismuth(V) complexes of lapachol: Synthesis, crystal structure and cytotoxic activity. Molecules 2011, 16, 10314-10323.
22. Sasmal, P.K.; Patra, A.K.; Nethaji, M.; Chakravarty, A.R. DNA cleavage by new oxovanadium(IV) complexes of N-salicylidene α-amino acids and phenanthroline bases in the photodynamic therapy window. Inorg. Chem. 2007, 46, 11112-11121.
23. 3+ binding and photocleavage properties by the complex with an intercalating ligand. J. Inorg. Biochem. 2010, 104, 697-703.
24. 2+. J. Am. Chem. Soc. 1990, 112, 4960-4962.
25. Zhang, K.Y.; Li, S.P.Y.; Zhu, N.; Or, I.W.S.; Cheung, M.S.H.; Lam, Y.W.; Lo, K.K.W. Structure, photophysical and electrochemical properties, biomolecular interactions, and intracellular uptake of luminescent cyclometalated iridium(III) dipyridoquinoxaline complexes. Inorg. Chem. 2010, 49, 2530-2540.
26. 3: DNA Interaction studies and biological activity against Leishmania (L) mexicana. J. Inorg. Biochem. 2007, 101, 111-116.
27. Benítez, J.; Guggeri, L.; Tomaz, I.; Pessoa, J.C.; Moreno, V.; Lorenzo, J.; Avilés, F.X.; Garat, B.; Gambino, D. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential anti-protozoa and anti-tumor agent. J. Inorg. Biochem. 2009, 103, 1386-1387.
28. Yin, H.D.; Zhai, J. Synthesis, characterizations and crystal structures of antimony(III) complexes with nitrogen-containing ligands. Inorg. Chim. Acta 2009, 362, 339-345.
29. Espínola, J.G.P.; Martins, E.P.S.; Aguiar, F.P.; Silva, H.R.M.; Fonseca, M.G.; Arakaki, L.N.H.; Teotôno, E.E.S. Thermal decomposition study of bismuth (III) trichloride complex with 1,10-phenanthroline as the ligand. J. Therm. Anal. Calorim. 2011, 106, 601-606.
30. Bertazzi, N.; Alonzo, G.; Gibb, T.C. Antimony-121 moessbauer and infrared spectral studies on 1,10-phenanthroline adducts of antimony(III) halides. Inorg. Chim. Acta 1983, 73, 121-124.
31. Shaw, J.J. Further thoughts on the use of the name Leishmania (Leishmania) infantum chagasi for the a etiological agent of American visceral leishmaniasis. Mem. Inst. Oswaldo Cruz 2006, 101, 577-579.
32. Marzochi, M.C.D.A.; Marzochi, K.B.F. Tegumentary and visceral leishmaniasis in Brazil emerging anthropozoonosis and possibilities for their control. Cad. Saúde Públ. 1994, 10, 359-375.
33. Sinagra, A.; Luna, C.; Abraham, D.; Iannella, M.D.C.; Riarte, A.; Krolewiecki, A.J. The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis in the golden hamster model. Rev. Soc. Bras. Med. Trop. 2007, 40, 627-630.
34. Navarro, M.; Cisneros-Fajardo, E.J.; Sierralta, A.; Fernandez-Mestre, M.; Silva, P.; Arrieche, D.; Marchán, E. Design of copper DNA intercalators with leishmanicidal activity. J. Biol. Inorg. Chem. 2003, 8, 401-408.
35. 2+. Polyhedron 1998, 17, 1525-1534.
36. 2+ conjugates and their photo cross-linking studies with the complementary DNA strand. J. Am. Chem. Soc. 2002, 124, 13416-13433.
37. 3(DPPZ) with Dipyridophenazine Ligand. Chin. Chem. Lett. 2003, 14, 43-46.
38. Sheldrick, G.M.S. SHELXL-97 - A Program for Crystal Structure Refinement; University of Goettingen: Goettingen, Germany, 1997.
39. Ouellette, M.; Borst, P. Drug-resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res. Microbiol. 1991, 142, 737-746.
40. Monte-Neto, R.L.; Coelho, A.C.; Raymond, F.; Légaré, D.; Corbeil, J.; Melo, M.N.; Frézard, F.; Ouellette, M. Gene Expression Profiling and Molecular Characterization of Antimony Resistance in Leishmania amazonensis. PLoS Negl. Trop. Dis. 2011, 5, e1167.
41. Ma, G.Y.; Khan, S.I.; Jacob, M.R.; Tekwani, B.L.; Li, Z.Q.; Pasco, D.S.; Walker, L.A.; Khan, L.A. Antimicrobial and antileishmanial activities of hypocrellins A and B. Antimicrob. Agents Chemother. 2004, 48, 4450-4452.
42. Habtemariam, S. In vitro antileishmanial effects of antibacterial diterpenes from two Ethiopian Premma species: P. chimperi and P. oligotricha. BMC Pharmacol. 2003, 3, 1-6.
43. Ouellette, M.; Fase-Fowler, F.; Borst, P. The amplified H circle of methotrexate-resistant leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J. 1990, 9, 1027-1033.
44. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
45. Wilson, J.J.; Lippard, S.J. In Vitro Anticancer Activity of cis-Diammineplatinum(II) Complexes with β-Diketonate Leaving Group Ligands. J. Med. Chem. 2012, 55, 5326-5336.